Inhibitor of nuclear factor kappa-B kinase complex (IKK complex) (IKK complex)

The Inhibitor of nuclear factor kappa-B kinase (IKK) complex is a multi-subunit enzyme that serves as the master regulator of the canonical NF-κB signaling pathway [1, 11]. It is typically composed of two catalytic subunits, IKKα (CHUK) and IKKβ (IKBKB), and a regulatory subunit, IKKγ (NEMO) [8, 11]. In response to stimuli such as pro-inflammatory cytokines or pathogens, the IKK complex phosphorylates IκB proteins, marking them for proteasomal degradation [2, 8]. This release allows NF-κB transcription factors to enter the nucleus and activate genes involved in immunity, inflammation, and cell survival [3, 10]. Dysregulation of the IKK complex is a hallmark of many cancers and chronic inflammatory diseases, making it a high-priority therapeutic target [4, 5, 13]. Pharmacological inhibition of the complex, particularly the IKKβ subunit, aims to suppress constitutive NF-κB activity and sensitize cells to apoptosis [4, 6]. However, developing IKK inhibitors has proven challenging due to significant safety concerns, including systemic toxicity and impaired immune function [5, 6]. These challenges have limited the clinical advancement of many candidates, though research continues into more selective or alternative targeting strategies [4, 5].

Other names

IκB kinase complexIKKα/IKKβ/NEMO complexIKK signalosomeIKK core complexInhibitor of kappa light polypeptide gene enhancer in B-cells kinase complex

Inhibition of the catalytic activity of the IKK complex (primarily the IKKβ subunit), which prevents the phosphorylation and subsequent proteasomal degradation of IκB proteins. This results in the sequestration of NF-κB transcription factors in the cytoplasm, thereby blocking the expression of pro-inflammatory and pro-survival genes.